$DOCS

Why Doximity Stock Is Up 80%

Doximity (NYSE:DOCS) shares jumped about 80% after CEO Jeffrey Tangney said its new AI search tool generates over 10 times more revenue per search than it costs. The company reported Q revenue up 7% to $156.6M and adjusted EBITDA of $74.8M, and raised full-year revenue guidance to $671M-$681M. FactSet said 17% of tradable shares were short before the report.

Original reporting
Published Aug 7, 2026, 7:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 7, 2026, 7:48 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Why Doximity Stock Is Up 80% — source image
Decision brief

The 30-second read

$DOCSBullishMed
01

Why it matters

Traders can reassess DOCS’s forward revenue trajectory and the sustainability of AI-search economics, while also accounting for squeeze-driven volatility.

02

Market read

DOCS combines a guidance raise with a specific AI-search unit-economics claim, but the magnitude of the move is amplified by short-covering.

03

What to watch

Short interest unwind (about 17% of tradable shares) can dominate near-term price action, making post-squeeze pullbacks more likely even if guidance is credible.

Relevance 8/10Novelty 7/10Timing: after-hours/next-session reaction to today’s earnings and AI-search margin comments

Background

The article frames the rally as a mix of earnings/guidance strength, new AI-search margin commentary, and mechanical short-covering.

Company-level read

Ticker impact

$DOCSBullishMedium confidence
Context

Doximity surged ~80% after CEO said its new AI search tool earns over 10x revenue versus running costs, alongside raised full-year guidance.

Expected impact

Likely elevated volatility and follow-through risk as traders parse whether the AI pipeline meaningfully contributes to results.

Evidence & confidence

The article provides new, attributable management commentary on AI-search unit economics and a specific guidance increase, but it also notes the AI pipeline contribution is viewed as limited by an analyst, which can cap upside after the initial squeeze.

Market effects

Highlights investor appetite for monetization and margin expansion narratives in healthcare software and AI-enabled search tools.

Primarily US small/mid-cap momentum flow; limited direct regional spillover described.

No direct global macro or cross-border transaction details beyond the US-focused platform.

Counterpoint

The AI pipeline may be “conservative” and not yet a major driver of the raised outlook, so the stock’s magnitude could overshoot fundamentals.

Key entities

  • Doximity

    Digital platform for US medical professionals; subject of the earnings/guidance and AI-search margin comments.

  • Jeffrey Tangney

    CEO who commented that AI search earns more than 10x revenue versus running costs.

  • Piper Sandler

    Cited as viewing the raised outlook as not significantly reflecting AI pipeline contribution.

  • FactSet

    Cited for short interest level ahead of the report.

Related articles

$DOCSHighAI 9/10

A Lesser-Known Stock Climbed More Than 100% In a Day After AI Surprise. Here’s Why.

Doximity (DXRX) shares jumped after the company reported fiscal Q1 2027 results and said its new AI search product is generating strong unit economics. CEO Jeffrey Tangney said revenue is over 10 times per search versus cost. Q1 revenue was $156.6M and adjusted EBITDA $74.8M. Full-year revenue guidance raised to $671M-$681M; short interest was about 17%, contributing to a short squeeze.

$DOCSHighAI 9/10

Doximity Raises Full-Year Guidance as AI Scribe Surges Tenfold, Clinical AI Tops Safety Study

Doximity (NYSE: DOCS) reported fiscal Q1 2027 results for the quarter ended June 30, 2026. Revenue was $156.6M, up 7% and above consensus $151.7M; adjusted EBITDA was $74.8M. The company raised full-year revenue guidance to $671M-$681M and said Doximity Scribe active users rose tenfold and its Ask ranked first in the NOHARM clinical AI safety study. DOCS shares jumped in premarket.

$DOCSMed

Doximity's stock skyrockets 50% on medical AI excitement. Can the rally last?

Doximity (DOCS) shares rose as much as 94% and were up about 50% after its earnings call, despite mixed results. Management highlighted medical AI progress, including a “winning model” with 4.8% error vs 13.6% for Anthropic’s Fable 5, and said it earns over 10x search revenue vs cost. FY revenue guidance was raised to $671M-$681M from $664M-$676M; adjusted EPS was 29 cents.

$DOCSHighAI 9/10

Doximity Soars After Q1 Revenue Tops Guidance; Raises FY2027 View

Doximity (DOCS) reported Q1 FY2027 revenue of $156.62M, up 7% and above its prior guidance range of $151M to $152M. Net income fell to $24.32M ($0.13/share) from $53.32M ($0.27). For Q2, it expects revenue of $170M to $171M and adjusted EBITDA of $80.5M to $81.5M. FY2027 revenue guidance was raised to $671M to $681M.